Federated Hermes Inc. Sells 96,345 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Federated Hermes Inc. reduced its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 9.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 936,107 shares of the company’s stock after selling 96,345 shares during the period. Federated Hermes Inc. owned approximately 0.44% of Hims & Hers Health worth $8,331,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new position in Hims & Hers Health in the 4th quarter worth approximately $48,000. EMC Capital Management increased its position in Hims & Hers Health by 80.0% in the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock worth $79,000 after buying an additional 5,332 shares during the period. Belpointe Asset Management LLC bought a new position in Hims & Hers Health in the 3rd quarter worth approximately $76,000. Custom Index Systems LLC bought a new position in Hims & Hers Health in the 4th quarter worth approximately $132,000. Finally, Corton Capital Inc. bought a new position in Hims & Hers Health in the 3rd quarter worth approximately $122,000. 63.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on HIMS. Guggenheim lifted their price target on Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Canaccord Genuity Group started coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective on the stock. SVB Leerink started coverage on Hims & Hers Health in a report on Monday, February 26th. They set a “market perform” rating and a $10.00 price objective on the stock. Jefferies Financial Group reissued a “hold” rating and set a $15.00 price objective (down previously from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Finally, Leerink Partnrs reissued a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.85.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 22,839 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $10.03, for a total value of $229,075.17. Following the transaction, the insider now owns 154,345 shares of the company’s stock, valued at $1,548,080.35. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Hims & Hers Health news, CEO Andrew Dudum sold 50,361 shares of the business’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $16.34, for a total value of $822,898.74. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Soleil Boughton sold 22,839 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $10.03, for a total value of $229,075.17. Following the sale, the insider now owns 154,345 shares of the company’s stock, valued at approximately $1,548,080.35. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 548,150 shares of company stock valued at $7,327,717. 31.63% of the stock is currently owned by corporate insiders.

Hims & Hers Health Stock Up 0.0 %

Shares of HIMS stock opened at $12.34 on Thursday. The stock’s fifty day simple moving average is $13.65 and its 200 day simple moving average is $9.99. Hims & Hers Health, Inc. has a one year low of $5.65 and a one year high of $17.16.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.03. The business had revenue of $246.60 million for the quarter, compared to analyst estimates of $245.84 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. Hims & Hers Health’s quarterly revenue was up 47.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.05) EPS. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.1 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.